Company · CIK 0002010788 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
EXOZYMES INC. · EXOZ
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 PForm 4 → | Sep 2, 7:33 pm EDT | Michael HeltzenChief Executive Officer | 855 | $7.49 | $6,405 | 13,953 | +6.53% | late |
| Aug 19, 2026 AForm 4 → | Sep 2, 7:33 pm EDT | Michael HeltzenChief Executive Officer | 8,841 | $6.40 | $56,582 | 13,853 | — | late |
| Aug 19, 2026 MForm 4 → | Aug 25, 7:16 pm EDT | Damien Alan PerrimanChief Commercial Officer | 19,612 | — | — | 28,499 | — | late |
| Aug 19, 2026 MForm 4 → | Aug 25, 6:57 pm EDT | Tyler Paz KormanChief Scientific Officer | 32,964 | — | — | 762,837 | — | late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 AForm 4 → | Sep 17, 5:27 pm EDT | Fouad NawazVice President- Finance | 45,000 | — | — | 45,000 | — | late |
| Aug 19, 2026 MForm 4 → | Aug 25, 7:16 pm EDT | Damien Alan PerrimanChief Commercial Officer | 19,612 | — | — | 43,147 | — | late |
| Aug 19, 2026 MForm 4 → | Aug 25, 6:57 pm EDT | Tyler Paz KormanChief Scientific Officer | 32,964 | — | — | 46,140 | — | late |